Radiological Patterns of Drug-induced Interstitial Lung Disease (DILD) in Early-phase Oncology Clinical Trials.
Angelika TerbuchCrescens TiuIrene Moreno CandilejoMariana ScarantiAndra CurceanDan BarMiriam Estevez TimonMalaka AmeratungaJoo Ern AngJonathan RatoffAnna R MinchomUdai BanerjiJohann S de BonoNina TunariuJuanita S LopezPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
DILD in early-phase clinical trials is a toxicity of variable onset, with diverse clinical and radiological findings. Radiological findings precede clinical symptoms. The extent of the affected lung parenchyma, scored by the RMH DILD score, correlates with clinical presentation. Most events are low grade, and improve with treatment interruption, which should be considered early.